317450 — Myung In Pharm Co Income Statement
0.000.00%
Last trade - 00:00- KR₩2tn
- KR₩1tn
- KR₩269bn
- 37
- 36
- 31
- 22
Annual income statement for Myung In Pharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 225,828 | 242,338 | 269,435 |
| Cost of Revenue | |||
| Gross Profit | 143,549 | 149,888 | 165,195 |
| Selling / General / Administrative Expenses | |||
| Depreciation and Amortization | |||
| Total Operating Expenses | 149,926 | 158,719 | 176,680 |
| Operating Profit | 75,903 | 83,618 | 92,754 |
| Gain / Loss on Sale of Assets | |||
| Total Net Non Operating Interest Income / Expense | |||
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | 81,817 | 92,061 | 88,075 |
| Provision for Income Taxes | |||
| Net Income After Taxes | 57,434 | 74,512 | 68,671 |
| Net Income Before Extraordinary Items | |||
| Net Income | 57,434 | 74,512 | 68,671 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | 57,434 | 74,512 | 68,671 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | 3,934 | 5,104 | 4,736 |
| Dividends per Share |